vs
Side-by-side financial comparison of BRUNSWICK CORP (BC) and Insulet Corporation (PODD). Click either name above to swap in a different company.
BRUNSWICK CORP is the larger business by last-quarter revenue ($1.4B vs $761.7M, roughly 1.8× Insulet Corporation). Insulet Corporation runs the higher net margin — 12.0% vs 1.5%, a 10.4% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 17.3%). Insulet Corporation produced more free cash flow last quarter ($89.5M vs $-116.8M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs -2.3%).
Brunswick Corporation, formerly known as the Brunswick-Balke-Collender Company, is an American corporation that has been developing, manufacturing and marketing a wide variety of products since 1845. Brunswick has more than 13,000 employees in 24 countries. Brunswick owns a number of brands, including Mercury Marine. In 2024, Brunswick reported sales of US$5.2 billion. Brunswick's global headquarters is in the northern Chicago suburb of Mettawa, Illinois.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
BC vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $761.7M |
| Net Profit | $21.0M | $91.1M |
| Gross Margin | 24.9% | 69.5% |
| Operating Margin | 3.6% | 16.0% |
| Net Margin | 1.5% | 12.0% |
| Revenue YoY | 17.3% | 33.9% |
| Net Profit YoY | — | 157.3% |
| EPS (diluted) | $0.32 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | $761.7M | ||
| Q4 25 | $1.3B | $783.7M | ||
| Q3 25 | $1.4B | $706.3M | ||
| Q2 25 | $1.4B | $649.1M | ||
| Q1 25 | $1.2B | $569.0M | ||
| Q4 24 | $1.2B | $597.5M | ||
| Q3 24 | $1.3B | $543.9M | ||
| Q2 24 | $1.4B | $488.5M |
| Q1 26 | $21.0M | $91.1M | ||
| Q4 25 | $18.7M | $101.6M | ||
| Q3 25 | $-235.5M | $87.6M | ||
| Q2 25 | $59.3M | $22.5M | ||
| Q1 25 | $20.2M | $35.4M | ||
| Q4 24 | $-82.5M | $100.7M | ||
| Q3 24 | $44.6M | $77.5M | ||
| Q2 24 | $100.0M | $188.6M |
| Q1 26 | 24.9% | 69.5% | ||
| Q4 25 | 23.1% | 72.6% | ||
| Q3 25 | 25.8% | 72.2% | ||
| Q2 25 | 25.5% | 69.7% | ||
| Q1 25 | 24.9% | 71.9% | ||
| Q4 24 | 21.9% | 72.1% | ||
| Q3 24 | 26.2% | 69.3% | ||
| Q2 24 | 27.1% | 67.7% |
| Q1 26 | 3.6% | 16.0% | ||
| Q4 25 | 3.1% | 18.7% | ||
| Q3 25 | -17.8% | 16.7% | ||
| Q2 25 | 7.1% | 18.7% | ||
| Q1 25 | 4.6% | 15.6% | ||
| Q4 24 | -4.8% | 18.3% | ||
| Q3 24 | 7.7% | 16.2% | ||
| Q2 24 | 11.0% | 11.2% |
| Q1 26 | 1.5% | 12.0% | ||
| Q4 25 | 1.4% | 13.0% | ||
| Q3 25 | -17.3% | 12.4% | ||
| Q2 25 | 4.1% | 3.5% | ||
| Q1 25 | 1.7% | 6.2% | ||
| Q4 24 | -7.1% | 16.9% | ||
| Q3 24 | 3.5% | 14.2% | ||
| Q2 24 | 6.9% | 38.6% |
| Q1 26 | $0.32 | $1.30 | ||
| Q4 25 | $0.32 | $1.42 | ||
| Q3 25 | $-3.59 | $1.24 | ||
| Q2 25 | $0.89 | $0.32 | ||
| Q1 25 | $0.30 | $0.50 | ||
| Q4 24 | $-1.21 | $1.38 | ||
| Q3 24 | $0.67 | $1.08 | ||
| Q2 24 | $1.48 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $277.8M | $480.4M |
| Total DebtLower is stronger | $490.2M | $18.6M |
| Stockholders' EquityBook value | $1.6B | $1.3B |
| Total Assets | $5.5B | $3.0B |
| Debt / EquityLower = less leverage | 0.31× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $277.8M | $480.4M | ||
| Q4 25 | $256.8M | — | ||
| Q3 25 | $297.7M | — | ||
| Q2 25 | $315.7M | — | ||
| Q1 25 | $286.7M | — | ||
| Q4 24 | $269.0M | — | ||
| Q3 24 | $284.1M | — | ||
| Q2 24 | $494.5M | — |
| Q1 26 | $490.2M | $18.6M | ||
| Q4 25 | $2.1B | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $1.6B | $1.3B | ||
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.6B | $1.4B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $1.9B | $1.2B | ||
| Q3 24 | $2.0B | $1.1B | ||
| Q2 24 | $2.0B | $998.4M |
| Q1 26 | $5.5B | $3.0B | ||
| Q4 25 | $5.3B | $3.2B | ||
| Q3 25 | $5.4B | $3.0B | ||
| Q2 25 | $5.8B | $3.5B | ||
| Q1 25 | $5.9B | $3.5B | ||
| Q4 24 | $5.7B | $3.1B | ||
| Q3 24 | $6.0B | $3.0B | ||
| Q2 24 | $6.4B | $2.9B |
| Q1 26 | 0.31× | 0.01× | ||
| Q4 25 | 1.30× | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | 1.25× | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $113.8M |
| Free Cash FlowOCF − Capex | $-116.8M | $89.5M |
| FCF MarginFCF / Revenue | -8.5% | 11.8% |
| Capex IntensityCapex / Revenue | 4.2% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | $344.6M | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $132.9M | $183.3M | ||
| Q3 25 | $140.4M | $125.7M | ||
| Q2 25 | $316.2M | $196.5M | ||
| Q1 25 | $-27.4M | $63.8M | ||
| Q4 24 | $306.4M | $147.7M | ||
| Q3 24 | $67.4M | $98.5M | ||
| Q2 24 | $211.0M | $96.5M |
| Q1 26 | $-116.8M | $89.5M | ||
| Q4 25 | $83.6M | $48.2M | ||
| Q3 25 | $106.5M | $100.1M | ||
| Q2 25 | $271.3M | $177.9M | ||
| Q1 25 | $-65.1M | $51.5M | ||
| Q4 24 | $276.1M | $94.1M | ||
| Q3 24 | $31.4M | $71.8M | ||
| Q2 24 | $163.9M | $74.0M |
| Q1 26 | -8.5% | 11.8% | ||
| Q4 25 | 6.3% | 6.2% | ||
| Q3 25 | 7.8% | 14.2% | ||
| Q2 25 | 18.7% | 27.4% | ||
| Q1 25 | -5.3% | 9.1% | ||
| Q4 24 | 23.9% | 15.7% | ||
| Q3 24 | 2.5% | 13.2% | ||
| Q2 24 | 11.4% | 15.1% |
| Q1 26 | 4.2% | 3.2% | ||
| Q4 25 | 3.7% | 17.2% | ||
| Q3 25 | 2.5% | 3.6% | ||
| Q2 25 | 3.1% | 2.9% | ||
| Q1 25 | 3.1% | 2.2% | ||
| Q4 24 | 2.6% | 9.0% | ||
| Q3 24 | 2.8% | 4.9% | ||
| Q2 24 | 3.3% | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | 7.11× | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 5.33× | 8.73× | ||
| Q1 25 | -1.36× | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | 1.51× | 1.27× | ||
| Q2 24 | 2.11× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BC
Segment breakdown not available.
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
